- TuHURA Biosciences, Inc. entered into a Secured Promissory Note and Loan Agreement on **October 27, 2025**, to secure a bridge loan of up to **$3,000,000** from Matthew Joseph Natchtrab Revocable Trust.  **[1498382_0001193125-25-260924_hura-ex10_1.htm:0]** **[1498382_0001193125-25-260924_hura-20251027.htm:1]** 
- An **initial advance of $1,500,000** was made on October 27, 2025, with the remaining amount available over a **30-day period**.  **[1498382_0001193125-25-260924_hura-ex10_1.htm:0]** **[1498382_0001193125-25-260924_hura-20251027.htm:1]**  The loan carries an **interest rate of 3% per month**.  **[1498382_0001193125-25-260924_hura-20251027.htm:1]** **[1498382_0001193125-25-260924_hura-ex10_1.htm:6]** 
- The loan is secured by a **first priority perfected security interest in the company's U.S. patents** related to its ImmuneFxTM technology platform.  **[1498382_0001193125-25-260924_hura-20251027.htm:1]** 
- The outstanding principal and accrued interest are due on the earlier of **December 31, 2025**, or **30 days** following the successful closing of an equity financing exceeding **$12,000,000**.  **[1498382_0001193125-25-260924_hura-20251027.htm:1]** **[1498382_0001193125-25-260924_hura-ex10_1.htm:1]**  A **$180,000 loan fee** is also payable at maturity.  **[1498382_0001193125-25-260924_hura-20251027.htm:1]** 
- In connection with the initial advance, the company issued a warrant to purchase up to **65,217 shares** of common stock, exercisable for **two years** from the issuance date.  **[1498382_0001193125-25-260924_hura-20251027.htm:1]**

TuHURA Biosciences, Inc./NV (HURA)